Cure My Disease

Don't miss your cure!

 Log in / Sign up

Barrett's esophagus treatment showdown: which procedure hurts less?

NCT ID NCT05051475

Disease control Sponsor: Centre of Postgraduate Medical Education Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compared two endoscopic treatments for Barrett's esophagus, a condition that can lead to esophageal cancer. The goal was to see which procedure—radiofrequency ablation or hybrid argon plasma coagulation—causes less pain and is safer from the patient's viewpoint. Sixty-two adults with Barrett's esophagus took part, and researchers measured pain right after the procedure, at 7 days, and at 30 days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
endoscopic radiofrequency ablation or hybrid argon plasma coagulation
What this could lead to
If one method proves more acceptable and safer, it could become the preferred treatment for Barrett's esophagus, reducing discomfort for patients.
What could go wrong
This is a small, completed study (62 people) comparing two established techniques, so it won't introduce a new treatment. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

62 people

The number who actually took part.

Started

Dec 2021

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female subjects over 18 years * Histologically and endoscopically proven Barrett's esophagus requiring ablation therapy according to the current guidelines * General health status sufficient to perform an endoscopic procedure (ASA I-III) Exclusion Criteria: * Primary or secondary coagulopathy, with INR\>1.5 and/or platelet count of \<75,000. * Anticoagulation therapy (e.g. warfarin) for high-risk condition and unable to withhold the medication temporarily * Recent myocardial infraction or other significant cardiovascular event within 6 months prior to recruitment * Patients under long-term care and/or within nursing facilities (e.g. psychosocial disorders, mental retardation) * Any history of esophageal resection surgery * Esophageal varices

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Barrett esophagus are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma Of Esophagus Barrett esophagus esophageal adenocarcinoma gastroesophageal reflux disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Barrett esophagus Esophageal adenocarcinoma Reflux disease

Contacts and locations

Locations

  • Medical Centre for Postgraduate Education

    Warsaw, 02-781, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.